A Phase I/II Study of Intrathecal Trastuzumab in HER-2 Positive Cancer with Leptomeningeal Metastases: Safety, Efficacy, and Cerebrospinal Fluid Pharmacokinetics.

Priya U KumthekarMichael J AvramAndrew B LassmanNancy U LinEudocia LeeSean A GrimmMargaret SchwartzKirsten L Bell BurdettRimas V LukasKaran DixitIsabella PerronHui ZhangWilliam J GradisharElena I PentsovaSuriya JeyapalanMorris D GrovesMichelle MeliskoJeffrey J Raizer

Published in: Neuro-oncology (2022)

This study suggests promise for potentially improved outcomes of HER-positive LMD patients when treated with intrathecal trastuzumab while remaining safe and well-tolerated for patients.

Keyphrases

end stage renal disease
newly diagnosed
cerebrospinal fluid
ejection fraction
chronic kidney disease
prognostic factors
squamous cell carcinoma
epidermal growth factor receptor
machine learning
young adults
metabolic syndrome
papillary thyroid
tyrosine kinase
childhood cancer